Russian Heart Failure Journal 2010year Clinical and hemodynamic effects of testosterone replacement therapy in patients with dilated cardiomyopathy


To access this material please log in or register

Register Authorize
2010/

Clinical and hemodynamic effects of testosterone replacement therapy in patients with dilated cardiomyopathy

Abdullaev T. A., Mardanov B. U., Kurbanov N. A.

Keywords: DCM, clinical and hemodynamic effects, therapy, testosterone

DOI: 10.18087/rhfj.2010.5.1399

Background. Extremely poor prognosis of patients with dilated cardiomyopathy (DCM), despite the use of recommended drugs, indicates the presence of additional pathogenetic mechanisms of disease progression. Objective. To study prevalence of androgen deficiency in patients with DCM. To study clinical and hemodynamic effects of testosterone replacement therapy (TRT) additionally to standard. Materials and methods. The study included 60 men with DCM (42.8±2.25 years). After evaluation of androgen deficiency prevalence, 34 patients from this cohort were divided into two groups to assess the efficacy of TRT. In addition ECG, Holter ECG monitoring, echocardiography, total testosterone (TT), luteinizing hormone (LH) and prostate specific antigen (PSA) serum levels, trophological status were assessed, questionnaire survey with AMS, IIEF-5 was performed. Results. In men with DCM androgen deficiency state develop alresdy at young age. Its prevalence in our study was 35 %. 12‑weeks TRT was safe and led to significant regression of hypogonadism clinical symptoms, improved erectile function, indicators of central and intracardiac hemodynamics (increase of SBP by 10.2 %, and LVEF – by 5.1 %).
  1. Jankowska EA, Greslo AB, Beil et al. Anemia in men with chronic heart failure: an element of multiple anabolic depletion. Eur J Heart Fail. 2006;5 (Suppl 1):132.
  2. Dobrzycki S, Korecki J, Serwatka W et al. The association of plasma endogenous androgens level with left ventricular function and coronary artery disease in men. European Journal of Heart Failure Supplements. 2004;3 (Suppl 1):17.
  3. Беленков Ю. Н., Татенкулова С. Н., Мареев В. Ю. и др. Иммунокор­ригирующие свойства статинов в лечении дилатационной кардиомиопатии. Журнал Сердечная недостаточность. 2008;9 (6):268–273.
  4. Мареев В. Ю., Ольбинская Л. И., Мартынов А. И. Проспективное, многоцентровое, открытое исследование эффективности и переносимо­сти КВАдроприла у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилатационной кардиомиопатией (Исследование КВАНК) Журнал Сердечная Недостаточность. 2007;8 (1):42–47.
  5. Верткин А. Л., Моргунов Л. Ю., Аринина Е. Н., Колосова Е. С. Дефицит тестостерона и соматическая патология. Лечащий врач. 2006;10:85–94.
  6. Мазо Е. Б. Современные методы коррекции андрогенодефицитных состояний у мужчин. Фарматека. 2006;10 (125):6–11.
  7. Simon D, Charles MA, Nahoul K et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the TELECOM study. J Clin Endocrinol Metab. 1997;82 (2):682–685.
  8. Jankowska EA, Maida J, Szklarska A et al. Adrenal and gonadal andropenia is related to clinical severity and increased mortality in men with chronic heart failure. Eur J Heart Fail. 2004;3 (Suppl 1):148.
  9. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91 (6):1995–2010.
  10. Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159 (5):507–514.
  11. Камалов А. А., Ефремов Е. А., Дорофеев С. Д., Климкин Д. А. Клинические аспекты применения современных препаратов тестостерона у мужчин. http://unimed-urolog.ru / articles / 15.php
  12. Araujo AB, O’Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89 (12):5920–5926.
  13. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003;87 (2-3):179–183.
  14. Malkin CJ, Pugh PJ, West JN et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27 (1):57–64.
  15. Jankowska EA, Biel B, Majda J et al. Prevalence of complex anabolic deficiency, and its relationships with clinical status and prognosis in men with chronic heart failure. Eur J Heart Fail. 2005;4 (Suppl 1):62.
  16. Heinemann LA. Aging Males’ Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest. 2005;28 (11 Suppl Proceedings):34–38.
  17. Jankowska EA, Biel B, Grezslo A et al. Depression in men with chronic heart failure: prevalence and hormone determinants. Eur J Heart Fail. 2007;6 (Suppl 1):78.
  18. Моргунов Л. Ю. Дефицит андрогенов и ассоциированная с ним патология в общесоматической практике. – Автореф. дис.…доктора мед. наук. Москва, 2008. – 48 с.
  19. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49 (6):822–830.
  20. Эль Мазбух А. М., Пушкарь Д. Ю. Сексуальная дисфункция у больных с расстройствами мочеиспускания при доброкачественной гиперплазии предстательной железы. Андрология и генитальная хирургия. 2005;2:12–20.
  21. Cappelleri JO, Siegel RL, Oslerloh I, Rosen RC. Relationship between patient self assessment of erectile function and the erectile function domain of the International Index of Erectile Function. Urology. 2000;56 (3):477–481.
  22. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5‑item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11 (6):319–326.
  23. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342 (24):1802–1813.
  24. Терещенко С, Жиров И, Казанцева Е, Мкртумян А. Препараты тестостерона в комплексной терапии хронической сердечной недостаточности. Врач. 2008;9:76–78.
  25. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003;24 (10):909–915.
  26. Pugh PJ, Jones RD, West JN et al. Testosterone treatment for men with chronic heart failure. Heart. 2004;90 (4):446–447.
  27. Верткин А. Л., Моргунов Л. Ю., Наумов А. В. и др. Эффективность тестостерона в комплексной терапии пациентов с сердечно-сосудистыми заболеваниями. Врач. 2007;4:75–78.
  28. Bai CX, Kurokawa J, Tamagawa M et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112 (12):1701–1710.
  29. Астапенко М. Г., Шанина В. А., Котельникова Г. П., Чепой В. М. К вопросу о сердечной патологии при инфекционном неспецифическом (ревматоидном) полиартрите. Терапевтический архив. 1965;37 (1):11.
  30. Deenadayalu VP, White RE, Stallone JN et al. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol. 2001;281 (4):H1720–1727.
  31. Курбанов Р. Д., Курбанов Н. А., Абдуллаев Т. А. Значение клинико-функциональных проявлений в прогнозе жизни больных дилатационной кардиомиопатией. Журнал Сердечная недостаточность. 2003;4 (3):25–27.
  32. Marsh JD, Lehmann MH, Ritchie RH et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98 (3):256–261.
  33. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail. 2007;9 (1):44–50.
  34. Арутюнов Г. П., Костюкевич О. И., Рылова Н. В. Применение сбалансированной смеси «Пептамен» для энтерального питания в лечении больных с ХСН. Журнал Сердечная Недостаточность. 2002;5 (5):221–225.
  35. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75 (4):1092–1098.
Abdullaev T. A., Mardanov B. U., Kurbanov N. A. Clinical and hemodynamic effects of testosterone replacement therapy in patients with dilated cardiomyopathy. Russian Heart Failure Journal. 2010;11(5):285-291.

To access this material please log in or register

Register Authorize
Ru En